In Vitro Antimicrobial Susceptibility of Ceftriaxone Sulbactam EDTA (CSE 1034) And Other Β Lactam/ Β Lactamase Inhibitors And Carbapenems Against Enterobacteriaceae:A Comparative Study

Emergence of multidrug resistance among enterobacteriaceae has limited the treatment options. Therefore, it’s high time to look ahead for newer possibilities. However, new antibiotic discovery and development has not kept pace with the existing demand of the same. An alternative aspect is use of potentiators of the already existing antibiotics the so called antibiotic adjuvants. The present study was designed to evaluate efficacy of new antibiotic adjuvant entity (AAE) Ceftriaxone-Sulbactam-EDTA (CSE 1034) in comparison to other commonly used β lactam/ β lactamase inhibitors (BL+BLIs) and with carbapenems among enterobacteriaceae isolates. A total of 285 enterobacteriaceae obtained from different clinical specimens during study period of January 2015 to December 2015 were included. Antimicrobial susceptibility testing was performed for CSE 1034 and compared with susceptibility of amoxicillin-clavalunic acid, ampicilln-sulbactam, piparacillin-tazobactam, imipenem and meropenem. Escherichia coli (60.35%) was the predominant enterobacteriaceae obtained. Susceptibility of CSE 1034 was found to be significantly higher (p value <0.00001) than other antibiotics tested. It is recommended to include CSE 1034 in routine antibiotic sensitivity panel of enterobacteriaceae isolates. It may be considered as promising carbapenems sparer.